Theut Riis Peter, Thorlacius Linnea R, Jemec Gregor B
a Department of Dermatology , University Hospital Zealand , Roskilde , Denmark.
b Health Sciences Faculty , University of Copenhagen , Copenhagen , Denmark.
Expert Opin Investig Drugs. 2018 Jan;27(1):43-53. doi: 10.1080/13543784.2018.1412430. Epub 2017 Dec 4.
Hidradenitis suppurativa is a chronic skin disease with a significant unmet need for treatment options. Randomized controlled trials are few and only a single drug (adalimumab) has Hidradenitis as a registered indication.
The clinicaltrials.gov and the EudraCT clinical trials register for reported trials on Hidradenitis Suppurativa was searched on the 22-06-2017. Trials for upcoming new drugs for HS are reported focusing on drugs in phase I and II trials.The clinicaltrials.gov and the EudraCT clinical trials register for reported trials on Hidradenitis Suppurativa was searched on the 22-06-2017. Trials for upcoming new drugs for HS are reported focusing on drugs in phase I and II trials.
Currently, MABp1, Secukinumab, CJM112, Apremilast and IFX-1 are being investigated in Phase I and II trials and offer theoretical and promising new treatment options. A trial with the drug MEDI8968 has been terminated with disappointing results. Metformin, Botulinum Toxin B, Provodine, Benzoyl Peroxide and intralesional triamcinolone are being tested as well. Treatment of Hidradenitis remains a challenge and quality RTCs are needed. Studies indicates a range of potential targets for therapy such as interleukin-1 and interleukin-17, but 'broad-spectrum' immunosuppressants like phosphodiesterase-4 inhibitors are being examined as well. A range of outcomes, including Physician Global Assessment, Sartorius scores and hidradenitis suppurativa clinical response are used in these trials, making future meta-analysis of the data difficult.
化脓性汗腺炎是一种慢性皮肤病，在治疗选择方面存在重大未满足需求。随机对照试验很少，只有一种药物（阿达木单抗）将化脓性汗腺炎作为注册适应症。
于2017年6月22日检索了clinicaltrials.gov和EudraCT临床试验注册库中关于化脓性汗腺炎的已报告试验。报告了即将用于化脓性汗腺炎的新药试验，重点关注处于I期和II期试验的药物。于2017年6月22日检索了clinicaltrials.gov和EudraCT临床试验注册库中关于化脓性汗腺炎的已报告试验。报告了即将用于化脓性汗腺炎的新药试验，重点关注处于I期和II期试验的药物。
目前，MABp1、司库奇尤单抗、CJM112、阿普斯特和IFX-1正在进行I期和II期试验研究，并提供了理论上有前景的新治疗选择。MEDI8968药物的一项试验已终止，结果令人失望。二甲双胍、肉毒杆菌毒素B、普罗沃定、过氧化苯甲酰和病灶内注射曲安奈德也正在进行测试。化脓性汗腺炎的治疗仍然是一项挑战，需要高质量的随机对照试验。研究表明一系列潜在的治疗靶点，如白细胞介素-1和白细胞介素-17，但磷酸二酯酶-4抑制剂等“广谱”免疫抑制剂也在接受研究。这些试验使用了一系列结果，包括医生整体评估、缝匠肌评分和化脓性汗腺炎临床反应，这使得未来对这些数据进行荟萃分析变得困难。
